Minutes of the HMPC meeting 22-24 September 2025

Antimicrobial resistance

Antimicrobial resistance – Act Now: Protect our present, secure our future

Human medicines European public assessment report (EPAR): Usgena, ustekinumab, Date of authorisation: 17/11/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Afinitor, everolimus, Date of authorisation: 02/08/2009, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Votubia, everolimus, Date of authorisation: 02/09/2011, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Maviret, glecaprevir,pibrentasvir, Date of authorisation: 26/07/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Date of authorisation: 03/07/2020, Revision: 11, Status: Authorised